PCP
TGTX icon

Perbak Capital Partners’s TG Therapeutics TGTX Stock Holding History

Perbak Capital Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,443
Closed -$214K – 226
2026
Q1 		$214K Buy
+6,443
New +$192K 0.05% 285
2025
Q2 		– Sell
-5,258
Closed -$207K – 332
2025
Q1 		$207K Buy
+5,258
New +$177K 0.15% 184

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Perbak Capital Partners's TGTX Position: Q2 2026 in Review

Perbak Capital Partners sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 6,443 shares — an estimated $214K sold.

Perbak Capital Partners first reported a position in TGTX in Q1 2025 and held it in 2 quarters. The position peaked at $214K in Q1 2026. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Perbak Capital Partners reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 6,443 TG Therapeutics shares in Q2 2026, an estimated $214K.
  • Perbak Capital Partners first reported a position in TG Therapeutics in Q1 2025 and held it in 2 quarters.
  • Perbak Capital Partners's TG Therapeutics position peaked at $214K in Q1 2026.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Perbak Capital Partners's 13F filing for Q2 2026.